CCL5 and neoplasm: Additionally, in a different set of prostate cancer preclinical models, the pharmacologic inhibition of protein kinase D blunted the production of SCF, CCL5, and CCL11 and led to decreased MC migration and reduced tumor growth in vivo [106].